Results 151 to 160 of about 48,696 (305)

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report

Majalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) increases the risk of having stroke as high as five fold. Anticoagulant administration such as vitamin K antagonist has been used regularly to reduce the occurence of stroke.
Alvin Nursalim, Yoga Yuniadi
doaj   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

British medical journal, 2015
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin. Design Retrospective, propensity matched cohort study. Setting: Optum Labs
N. Abraham, Sonal Singh, G. Alexander, H. Heien, L. Haas, W. Crown, N. Shah   +6 more
semanticscholar   +1 more source

Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need? [PDF]

, 2009
Russell D. Hull
openalex   +1 more source

Dabigatran Challenges Warfarin’s Superiority for Stroke Prevention in Atrial Fibrillation [PDF]

, 2010
Neil Schwartz, Gregory W. Albers
openalex   +1 more source

Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays

International Journal of Laboratory Hematology, Volume 47, Issue 5, Page 989-991, October 2025.
Agathe Herb, Jordan Wimmer, Laurent Mauvieux, Laurent Sattler   +3 more
wiley   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A. Dubois, Adam F. Cohen
openaire   +3 more sources

Dabigatran after cardiac surgery: Caution advised [PDF]

, 2011
Alexander Kulik, Mark B. Saltzman, James J. Morris   +2 more
openalex   +1 more source

Dabigatran versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2009
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin   +19 more
semanticscholar   +1 more source